Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 14/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4701030 | 0.89 | GRM5 (0.75) | GRM5 | |
| SCHEMBL4297614 | 0.86 | GRM5 (1.00) | GRM5 | |
| SCHEMBL4699294 | 0.85 | GRM5 (1.00) | GRM5 | |
| SCHEMBL13683915 | 0.81 | GRM5 (1.00) | GRM5 | |
| SCHEMBL6165528 | 0.80 | GRM5 (0.84) | GRM5 | |
| SCHEMBL4701529 | 0.79 | GRM5 (0.64) | GRM5 | |
| SCHEMBL4699480 | 0.79 | GRM5 (0.81) | GRM5 | |
| SCHEMBL4699464 | 0.79 | GRM5 (1.00) | GRM5 | |
| SCHEMBL4700004 | 0.77 | GRM5 (0.78) | GRM5 | |
| SCHEMBL4158354 | 0.77 | GRM5 (1.00) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1434773-B1 | HETEROARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2008-05-21 | — | — | EP | claimed |
| US-20040186295-A1 | Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5 | MERCK SHARP & DOHME LLC | 2004-09-23 | — | — | US | claimed |
| WO-2004030637-A2 | TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE | MERCK & CO., INC. (US) | 2004-04-15 | — | — | WO | claimed |
| EP-1996558-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007104538-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | disclosed |
| US-7253190-B2 | Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5 | MERCK & CO., INC. (US) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186295-A1 | Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5 | GRM5, GRM1, GRIK5 | GRM5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.